(Q33375317)

26 July 2017

title

Rituximab monotherapy is highly effective in splenic marginal zone lymphoma (English)

1 reference

splenic marginal zone lymphoma

26 July 2017

main subject

1 reference

1 reference

Kalpadakis C

1

1 reference

26 July 2017

Pangalis GA

2

1 reference

26 July 2017

Dimopoulou MN

3

1 reference

26 July 2017

Vassilakopoulos TP

4

1 reference

26 July 2017

Kyrtsonis MC

5

1 reference

26 July 2017

Korkolopoulou P

6

1 reference

26 July 2017

Kontopidou FN

7

1 reference

26 July 2017

Siakantaris MP

8

1 reference

26 July 2017

Dimitriadou EM

9

1 reference

26 July 2017

Kokoris SI

10

1 reference

26 July 2017

Tsaftaridis P

11

1 reference

26 July 2017

Plata E

12

1 reference

26 July 2017

Angelopoulou MK

13

1 reference

26 July 2017

publication date

1 September 2007

1 reference

26 July 2017

published in

Hematological Oncology

1 reference

26 July 2017

volume

25

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

127-131

1 reference

Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients

26 July 2017

cites work

1 reference

7 January 2021

Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients

1 reference

7 January 2021

Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes

1 reference

7 January 2021

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

1 reference

7 January 2021

Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hématologie Cellulaire (GFHC)

1 reference

7 January 2021

Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes

1 reference

7 January 2021

Treatment of indolent lymphomas from watch and wait to high dose therapy

1 reference

7 January 2021

Low dose 2-CdA schedule activity in splenic marginal zone lymphomas.

1 reference

7 January 2021

Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes

1 reference

7 January 2021

Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes

1 reference

7 January 2021

Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma

1 reference

7 January 2021

Immunotherapeutic and immunoregulatory drugs in haematologic malignancies

1 reference

7 January 2021

Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy

1 reference

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

7 January 2021

Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.820

1 reference

26 July 2017

1 reference